Gufic Biosciences Limited (GUFICBIO) reported revenue of ₹261 Cr and net profit of ₹22.31 Cr for the quarter ended 2026-06-30. Figures are parsed from the company's filed results.
GUFICBIO fundamentals, Fundamental score 48/100
The statements below are read from Gufic Biosciences Limited’s filed results, 12 filed quarters and 3 fiscal years on record, consolidated basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: Q1 FY26-27 · filed Aug 15, 2026 · audited
Quarterly resultsConsolidated
₹ Cr
Sep2023
Dec2023
Mar2024
Jun2024
Sep2024
Dec2024
Mar2025
Jun2025
Sep2025
Dec2025
Mar2026
Jun2026Latest
YoYlatest
Sales
215
202
195
203
204
208
205
224
237
231
252
261
+16.6%
176
165
161
167
166
174
179
190
199
198
205
214
+12.5%
Operating profit
39.4
36.5
34.2
35.8
38.6
33.9
26.4
33.3
37.8
33.0
47.2
46.6
+40.0%
OPM %
18.3%
18.1%
17.6%
17.6%
18.9%
16.3%
12.9%
14.9%
16.0%
14.3%
18.7%
17.9%
+3.0 pp
Other income
0.33
0.42
0.88
1.25
0.11
1.86
0.39
0.93
2.12
0.79
-1.17
0.46
-50.6%
Interest
4.46
3.18
3.65
4.62
5.18
4.91
8.40
9.23
9.58
8.36
9.44
9.32
+0.9%
Depreciation
4.30
4.14
4.34
4.31
4.30
4.62
7.84
7.72
7.77
7.69
7.65
7.71
-0.2%
Profit before tax
30.9
29.6
27.1
28.1
29.3
26.3
10.5
17.3
22.6
17.7
29.0
30.0
+73.9%
Tax %
25.0%
24.7%
26.1%
25.8%
25.6%
26.5%
26.7%
24.3%
25.6%
29.9%
24.4%
25.7%
+1.4 pp
Net profit
23.2
22.3
20.0
20.9
21.8
19.3
7.72
13.1
16.8
12.4
21.9
22.3
+70.7%
EPS (₹)
2.39
2.23
2.00
2.08
2.17
1.93
0.77
1.30
1.68
1.24
2.18
2.22
+70.8%
One column per filed quarter · ₹ crore · YoY = latest vs the same quarter a year back · EPS restated for bonus/split↔ scroll for earlier quarters
Revenue & net profit trend
last 12 quarters
RevenueNet profit
Revenue & net profit — Consolidated12 quarters
Segment results
Needs segment dataSegment results not parsedPer-segment revenue, EBIT margin and YoY arrive once we parse the segment annexure from the filing.
Forensic checksauto-scanned from the filing
Coming soonForensic checks not connectedAuditor opinion, OCF÷PAT, contingent liabilities, related-party share and working-capital days arrive as we parse the notes-to-accounts + cash-flow statement. Promoter-pledge is already on the Holdings tab.
How results moved the priceEOD reaction on the session the market could trade the filing
Avg absolute result-day move ±3.1%· EPS surprise: no estimates source
Q1'27filed Fri 14 Aug 19:39 · first tradeable session Mon 17 Auggap −5.2%close −0.9%
Q4'26filed Fri 29 May 22:13 · first tradeable session Mon 1 Jungap +2.4%close +3.8%
Q3'26filed Fri 13 Feb 22:33 · first tradeable session Mon 16 Febgap −1.5%close −5.3%
Q2'26filed Fri 14 Nov 19:18 · first tradeable session Mon 17 Novgap +0.3%close −1.5%
Q1'26filed Wed 13 Aug 19:01 · first tradeable session Thu 14 Auggap +0.9%close −0.1%
Q4'25filed Fri 30 May 19:37 · first tradeable session Mon 2 Jungap −7.9%close −6.4%
Q3'25filed Fri 14 Feb 18:27 · first tradeable session Mon 17 Febgap −6.6%close +0.4%
Q2'25filed Thu 14 Nov 19:33 · first tradeable session Mon 18 Novgap +0.1%close −8.3%
Q1'25filed Wed 14 Aug 15:20 · traded that sessiongap +0.5%close −2.6%
Q4'24filed Wed 29 May 20:54 · first tradeable session Thu 30 Maygap −1.2%close −2.5%
Q3'24filed Wed 14 Feb 17:57 · first tradeable session Thu 15 Febgap −1.8%close −3.0%
Q2'24filed Thu 9 Nov 17:57 · first tradeable session Fri 10 Novgap +1.0%close −1.6%
Q1'24filed Fri 11 Aug 17:27 · first tradeable session Mon 14 Auggap +1.5%close +4.0%
Q4'23filed Mon 29 May 18:57 · first tradeable session Tue 30 Maygap −1.9%close −4.7%
Q3'23filed Fri 10 Feb 18:33 · first tradeable session Mon 13 Febgap −0.3%close −3.1%
Q2'23filed Fri 11 Nov 19:30 · first tradeable session Mon 14 Novgap −2.2%close −4.2%
Q1'23filed Thu 11 Aug 21:14 · first tradeable session Fri 12 Auggap −1.4%close −1.0%
